McDermott + Bull has successfully placed Joshua (Josh) Woolley as Vice President of Clinical Affairs and Regulatory at Aria CV. Josh will be responsible for launching the company’s early feasibility study and leading ongoing engagements with the FDA to drive product approval. He will also be responsible for designing and executing pivotal studies as he works closely with the product development team to ensure products have the proper features for clinician use. 

Josh brings extensive clinical experience, particularly within cardiac devices. Most recently, he developed and executed NuPulse’s entire clinical, marketing, and customer support structures, while boosting sales during an FDA approved feasibility trial. Additionally, he developed the company’s clinical program to include a network of over 50 cardiovascular surgical sites and a team of clinical specialists supporting cases in the U.S. His experience building feasibility and pivotal trial protocols, site assessments and qualifications, and clinical procedures makes him an excellent fit for Aria CV. 

Based in St. Paul, Minnesota, Aria CV was founded in 2010 by Doctor John Scandurra and Doctor Karl Vollmers, following development work the two had done at the University of Minnesota’s Earl E. Bakken Medical Devices Center. Aria CV has performed a successful acute first in human clinical study in Vienna, Austria and is now preparing for a U.S. clinical trial under the FDA’s early feasibility study to evaluate long-term implants in Pulmonary Arterial Hypertension (PAH) patients. 

This executive search was completed by McDermott + Bull Partner Ken Dropiewski, Director Shelby Varon, Senior Executive Recruiter Allison Cox, and Research Associate Michael Matranga.